A bill to provide for certain requirements relating to cloud, data infrastructure, and foundation model procurement.

A bill to amend title XVIII of the Social Security Act to limit the coinsurance amount for certain services furnished in an ambulatory surgical center.

A bill to amend the California Desert Protection Act of 1994 to expand the boundary of Joshua Tree National Park, to redesignate the Cottonwood Visitor Center at Joshua Tree National Park as the "Dianne Feinstein Visitor Center", and for other purposes.

A bill to direct the Attorney General to prepare a report on the Department of Justice activities related to countering Chinese national security threats, and for other purposes.

A bill to protect the United States from artificial intelligence applications based in or affiliated with countries of concern, and for other purposes.

A bill to end unemployment payments to jobless millionaires.

A bill to exempt the Secretary of Energy of certain prohibitions with respect to an unmanned aircraft system, and for other purposes.

A bill to amend the Internal Revenue Code of 1986 to make permanent the 7-year recovery period for motorsports entertainment complexes.

Supersonic Aviation Modernization ActThis bill directs the Federal Aviation Administration (FAA) to allow civil aircraft to operate at speeds above Mach 1 (i.e., supersonic) over land in the United States under certain conditions.Specifically, the FAA must issue or revise regulations to allow for the operation of civil aircraft at speeds greater than Mach 1 in the national airspace system without a special authorization, so long as no sonic boom reaches the ground in the United States.Current regulations prohibit civil aircraft from operating above Mach 1 speeds over land in the United States without a special flight authorization issued by the FAA.

A bill to amend the Water Infrastructure Finance and Innovation Act of 2014 with respect to budgetary treatment of certain amounts of financial assistance, and for other purposes.

A bill to amend the Internal Revenue Code of 1986 to allow a credit against tax for charitable donations to nonprofit organizations providing education scholarships to qualified elementary and secondary students.

A bill to amend the Higher Education Act of 1965 to prohibit graduate medical schools from receiving Federal financial assistance if such schools adopt certain policies and requirements relating to diversity, equity, and inclusion.

A bill to amend title XVIII of the Social Security Act to establish requirements with respect to the use of prior authorization under Medicare Advantage plans.

A bill to amend section 235 of the Immigration and Nationality Act to treat inadmissible aliens more consistently regardless of their country of nationality, and for other purposes.

Prescription Drug Price Relief Act of 2025This bill requires the Department of Health and Human Services (HHS) to review brand-name drugs annually for excessive pricing and, if a drug is found to be priced excessively, to void any exclusivity granted to its sponsor.Specifically, HHS must review all brand-name drug prices at least annually and upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.An entity accepting an open, nonexclusive license under these provisions must pay a reasonable royalty to the holder of the relevant patent or approved new drug application, and must price the generic drug or biosimilar below the excessive rate.Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of these countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population.The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.